# Alethio Therapeutics

**Source:** https://www.startuphub.ai/startups/alethio-therapeutics
**Profile type:** Startup

> Biopharmaceutical company developing next-generation therapies for myeloproliferative neoplasms (MPNs), a group of chronic blood cancers.

## About

Alethio Therapeutics is a biopharmaceutical company focused on developing targeted, next-generation therapies designed to selectively eliminate disease-driving cells in myeloproliferative neoplasms (MPNs) and modify underlying disease progression. The company leverages its ARTEMIS discovery engine, which integrates patient-derived data, advanced 'omics, machine learning, and organoid models, to identify and validate novel targets for these blood cancers.

## Key facts

- **Slug:** alethio-therapeutics
- **Website:** https://alethiotherapeutics.com
- **Location:** Oxford, United Kingdom
- **Founded:** 2021-01-01
- **Operating status:** Active
- **Total funding:** $90M
- **Sectors / tags:** Biotechnology, Biopharmaceuticals, Healthcare, Oncology, Biotech

## StartupHub.ai scores

- **Ahrefs DR:** 6/100
- **Agent Readiness:** D (45/100)
- **Site Speed:** 74/100
- **Data Trust:** 60/100

## Funding rounds

| Date | Round | Amount | Lead investors |
| --- | --- | --- | --- |
| 1 Nov 2026 | [Series A](https://www.startuphub.ai/investment_rounds/alethio-therapeutics-series-a-2026) | $90M | [Sofinnova Partners](https://www.startuphub.ai/investors/sofinnova-partners), [RA Capital](https://www.startuphub.ai/investors/ra-capital) |

## Tech stack

Detected on alethiotherapeutics.com, last scanned 2026-11-06.

- **Hosting:** Google Cloud
- **Email provider:** Microsoft 365

## JSON-LD

Structured data aligned with this page's `<script type="application/ld+json">` (included when the profile is server-rendered).

```json
{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "BreadcrumbList",
      "itemListElement": [
        {
          "@type": "ListItem",
          "position": 1,
          "name": "Home",
          "item": "https://www.startuphub.ai"
        },
        {
          "@type": "ListItem",
          "position": 2,
          "name": "Startups",
          "item": "https://www.startuphub.ai/startups"
        },
        {
          "@type": "ListItem",
          "position": 3,
          "name": "Alethio Therapeutics",
          "item": "https://www.startuphub.ai/startups/alethio-therapeutics"
        }
      ]
    },
    {
      "@type": "ProfilePage",
      "@id": "https://www.startuphub.ai/startups/alethio-therapeutics#webpage",
      "url": "https://www.startuphub.ai/startups/alethio-therapeutics",
      "name": "Alethio Therapeutics - AI Startup Profile | StartupHub.ai",
      "description": "This is the StartupHub.ai profile of Alethio Therapeutics. Alethio Therapeutics is a startup founded in 2021, operating in Biotechnology and Biopharmaceuticals. Biopharmaceutical company developing next-generation therapies for myeloproliferative neoplasms (MPNs), a group of chronic blood cancers. Headquartered in Oxford, United Kingdom.",
      "dateModified": "2026-11-06T16:05:01.926Z",
      "mainEntity": {
        "@type": "Organization",
        "@id": "https://www.startuphub.ai/startups/alethio-therapeutics#organization"
      }
    },
    {
      "@type": "Organization",
      "@id": "https://www.startuphub.ai/startups/alethio-therapeutics#organization",
      "name": "Alethio Therapeutics",
      "url": "https://alethiotherapeutics.com",
      "logo": "https://cdn.startuphub.ai/storage/v1/object/public/entity-images/logos/eb9c2579-f143-416f-898a-44a2315dd104-square.webp",
      "image": "https://cdn.startuphub.ai/storage/v1/object/public/entity-images/logos/eb9c2579-f143-416f-898a-44a2315dd104-square.webp",
      "description": "Alethio Therapeutics is a biopharmaceutical company focused on developing targeted, next-generation therapies designed to selectively eliminate disease-driving cells in myeloproliferative neoplasms (MPNs) and modify underlying disease progression. The company leverages its ARTEMIS discovery engine, which integrates patient-derived data, advanced 'omics, machine learning, and organoid models, to identify and validate novel targets for these blood cancers.",
      "foundingDate": "2021-01-01",
      "address": {
        "@type": "PostalAddress",
        "addressLocality": "Oxford",
        "addressCountry": "GB"
      },
      "knowsAbout": [
        "Biotechnology",
        "Biopharmaceuticals",
        "Healthcare",
        "Oncology",
        "Biotech"
      ]
    }
  ]
}
```